Segall Bryant & Hamill LLC Takes $712,000 Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Segall Bryant & Hamill LLC acquired a new position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 45,100 shares of the company's stock, valued at approximately $712,000.

Other large investors have also modified their holdings of the company. Robeco Institutional Asset Management B.V. increased its holdings in Dr. Reddy's Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after purchasing an additional 9,373,412 shares during the period. Aikya Investment Management Ltd grew its position in shares of Dr. Reddy's Laboratories by 416.1% during the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after buying an additional 4,523,303 shares in the last quarter. Vanguard Group Inc. raised its holdings in Dr. Reddy's Laboratories by 397.2% in the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after acquiring an additional 3,911,404 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Dr. Reddy's Laboratories by 402.5% in the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock worth $38,981,000 after acquiring an additional 1,977,419 shares during the last quarter. Finally, State Street Corp grew its holdings in Dr. Reddy's Laboratories by 1.9% during the 3rd quarter. State Street Corp now owns 909,905 shares of the company's stock worth $72,292,000 after acquiring an additional 16,641 shares in the last quarter. Hedge funds and other institutional investors own 3.85% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RDY. Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th. StockNews.com cut Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th.

Dr. Reddy's Laboratories Stock Down 0.1 %

RDY stock traded down $0.02 during midday trading on Monday, reaching $13.19. 2,517,756 shares of the company were exchanged, compared to its average volume of 1,322,290. The company has a market cap of $11.01 billion, a price-to-earnings ratio of 21.00 and a beta of 0.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy's Laboratories Limited has a 1-year low of $12.50 and a 1-year high of $16.89. The stock's 50-day simple moving average is $13.48 and its 200 day simple moving average is $14.60.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, equities analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.